Phasei Clinical News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Phasei Clinical. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Phasei Clinical Today - Breaking & Trending Today

BioNTech to Present Clinical Data Updates for Personalized mRNA-based and Targeted Oncology Candidates at AACR 2024

Published: March 11, 2024

MAINZ, Germany, March 11, 2024 – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will present clinical trial data for selected candidates from its oncology pipeline at the American Association for Cancer Research (“AACR”) Annual Meeting 2024 in San Diego, California, from April 5-10, 2024. The oral and poster presentations will feature BioNTech’s investigational mRNA-based cancer vaccine and novel investigational antibody-drug conjugate (“ADC”) approaches. “This year’s AACR presentations

Source: yahoo.com

Related Topics:

BioNTech to Present Clinical Data Updates for Personalized mRNA-based and Targeted Oncology ...

Published: March 11, 2024

Source: smdailyjournal.com

Related Topics:

United States San Diego Fosun Pharma Roche Group American Association For Cancer Research American Association Cancer Research Annual Meeting Chief Medical Officer Phasei Clinical Poster Section Phasei Clinical Trials New Technologies Duality Biologics Private Securities Litigation Reform Act

Uvax Bio Receives Approval to Initiate a Phase 1 Clinical Trial of Novel HIV-1 Protein Nanoparticle Vaccine Candidates in Australia

Published: December 19, 2023

NEWARK, Del.--(BUSINESS WIRE)--Uvax Bio, LLC, a privately held, clinical-stage vaccine company, today announced acknowledgement from Australian Therapeutic Goods Administration and approval from the

Source: ibtimes.com.au

Related Topics:

United States Ji Li Jiang Zhu Uvax Bio Kevin Oneill Nucleus Network Centers For Disease Scripps Research United Nations Programme Human Research Ethics Committee Australian Therapeutic Goods Administration Avance Clinical Phasei Clinical Joint United Nations Programme Disease Control Corporate Strategy

Avstera Therapeutics Announces FDA Clearance of IND Application for AVS100, a Novel Highly Selective HDAC6 Inhibitor Targeting Solid Tumors

Published: December 18, 2023

/PRNewswire/ -- Avstera Therapeutics Corp, an oncology-focused biotech dedicated to addressing the large disease burden and significant unmet need of cancer...

Source: prnewswire.com

Related Topics:

United States Alejandro Villagra Apostoliam Tsimberidou Ajay Raju Karthik Musunuri Prnewswire Avstera Therapeutics Corp Md Anderson Cancer Center Georgetown University Associate Professor Therapeutics Corp Investigational New Drug Scientific Advisory Board Phasei Clinical Objective Response Rate Progression Free Survival Cancer Center Statements Regarding Forward Looking Private Securities Litigation Reform Act Avstera Therapeutics Corp

BioRay Announces First-Patient-In for Phase I Clinical Study of BRY812, a Novel LIV-1 Targeting Antibody Drug Conjugate

Published: November 7, 2023

/PRNewswire/ -- BioRay Pharmaceutical Co., Ltd. (hereinafter referred to as BioRay) announced that the first patient has been dosed in the Phase I Clinical...

Source: prnewswire.com

Related Topics:

San Diego United States Zhu Wei Yao Herui Prnewswire Bioray Pharmaceutical Co Ltd Phasei Clinical Sun Yat Sen Memorial Hospital Sun Yat Sen University Song Erwei Professor Yao Bioray Pharmaceutical Co

Page 2 Page 3 Page 4 Page 5